Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Tactile Medical Appoints Andrea Pearson to Board

Tactile Systems Technology, Inc. ("Tactile Medical") has announced the appointment of Andrea Pearson to its Board of Directors and as a member of the Compliance & Reimbursement and Nominating & Corporate Governance Committees, effective March 9, 2026. Andrea Pearson is an accomplished senior executive with over 25 years of experience in scaling healthcare organizations. She has served in various leadership roles, including as Growth Advisor and Chief Marketing Officer at Harbor Health, Chief Growth Officer at DispatchHealth, and in multiple executive roles at HealthGrades.

The company's Chairman of the Board, Bill Burke, expressed his delight in welcoming Andrea to the Board of Directors, highlighting her strong track record in driving growth and innovation, as well as her deep understanding of patient engagement within the healthcare ecosystem.

Tactile Medical, also known as Tactile Systems Technology, Inc., is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic inflammatory lung disease. The company collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs, and improve the quality of life for tens of thousands of patients each year.

The press release does not contain financial metrics or comparisons to previous periods. Following these announcements, the company's shares moved -0.1%, and are now trading at a price of $30.46. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS